Mediar is developing therapeutics that target fibrotic mediators to neutralize myofibroblasts, the key cells responsible for collagen deposition and organ scarring in fibrosis. This approach aims to slow disease progression and promote tissue regeneration in patients suffering from fibrotic diseases.
Funding
$124.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Fibrotic diseases lead to organ scarring and failure due to excessive collagen deposition by myofibroblasts. Current treatments often fail to address the root cause of fibrosis, leaving a significant unmet need for therapies that can halt disease progression and promote tissue regeneration.
Solution
Mediar is developing antibody therapeutics that target fibrotic mediators, a class of proteins responsible for activating myofibroblasts. By neutralizing these mediators, Mediar's approach aims to disable myofibroblasts, the key cells driving collagen deposition and organ scarring in fibrotic diseases. This therapeutic strategy has the potential to slow or halt disease progression and enable tissue regeneration. Furthermore, fibrotic mediators are measurable in plasma and correlate with disease severity, offering opportunities for precision medicine approaches in treating patients with fibrosis.
Target Audience
The primary target audience includes patients suffering from fibrotic diseases, as well as physicians and researchers specializing in pulmonology, hepatology, and other fields related to organ fibrosis.
Features
- Antibody therapeutics designed to neutralize fibrotic mediators
- Targets myofibroblast activation to reduce collagen deposition
- Aims to slow or halt the progression of fibrotic diseases
- Potential to promote tissue regeneration in affected organs
- Fibrotic mediators serve as potential biomarkers for disease severity and treatment response